Zanubrutinib for the treatment of relapsed/refractory hairy cell leukemia

Constantine S. Tam, Judith Trotman, Stephen Opat, Jennifer C. Stern, Heather Allewelt, Kunthel By, William Novotny, Jane Huang, and Alessandra Tedeschi The Alfred Hospital, Monash University, Melbourne, VIC, Australia; Concord Repatriation General Hospital, Concord, NSW, Australia; The University of Sydney, Concord, NSW, Australia; Monash Health, Clayton, VIC, Australia; Monash University, Clayton, VIC, Australia; BeiGene, San Mateo, CA; and ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

[1]  M. Dimopoulos,et al.  Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies , 2021, Blood advances.

[2]  S. Opat,et al.  Clinical pharmacology and PK/PD translation of the second-generation Bruton’s tyrosine kinase inhibitor, zanubrutinib , 2021, Expert review of clinical pharmacology.

[3]  X. Troussard,et al.  Patients with relapsed/refractory hairy‐cell leukemia , 2021, Cancer reports.

[4]  Jeffrey A Jones,et al.  Phase 2 Study of Ibrutinib in Classic and Variant Hairy Cell Leukemia. , 2021, Blood.

[5]  M. Dimopoulos,et al.  A RANDOMIZED PHASE 3 TRIAL OF ZANUBRUTINIB VERSUS IBRUTINIB IN SYMPTOMATIC WALDENSTRÖM MACROGLOBULINEMIA:THE ASPEN STUDY. , 2020, Blood.

[6]  R. Elstrom,et al.  Phase 1 study of selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. , 2019, Blood.

[7]  S. Swerdlow.  WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .

[8]  Jeffrey A Jones,et al.  Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. , 2017, Blood.

[9]  J. Cerhan,et al.  2016 US lymphoid malignancy statistics by World Health Organization subtypes , 2016, CA: a cancer journal for clinicians.

[10]  A. Rohatiner,et al.  Long‐term follow‐up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis , 2009, British journal of haematology.